LSV Asset Management Boosts Stock Position in Embecta Corp. $EMBC

LSV Asset Management lifted its position in Embecta Corp. (NASDAQ:EMBC) by 92.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 552,582 shares of the company’s stock after purchasing an additional 265,482 shares during the quarter. LSV Asset Management’s holdings in Embecta were worth $6,565,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Larson Financial Group LLC boosted its holdings in shares of Embecta by 368.6% in the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares in the last quarter. Wexford Capital LP purchased a new position in shares of Embecta in the 3rd quarter worth about $94,000. Tower Research Capital LLC TRC boosted its holdings in shares of Embecta by 542.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after purchasing an additional 6,224 shares in the last quarter. iSAM Funds UK Ltd purchased a new position in shares of Embecta in the 3rd quarter worth about $115,000. Finally, Neuberger Berman Group LLC purchased a new position in shares of Embecta in the 3rd quarter worth about $143,000. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on EMBC. Wall Street Zen cut Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. BTIG Research cut Embecta from a “buy” rating to a “neutral” rating in a report on Tuesday, May 5th. Mizuho dropped their target price on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Bank of America dropped their target price on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a report on Monday, May 18th. Finally, Zacks Research cut Embecta from a “hold” rating to a “strong sell” rating in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Strong Sell” and an average target price of $11.00.

Embecta Price Performance

EMBC opened at $3.32 on Wednesday. The business has a 50 day simple moving average of $7.22 and a two-hundred day simple moving average of $10.09. The firm has a market capitalization of $196.98 million, a price-to-earnings ratio of 1.75 and a beta of 1.09. Embecta Corp. has a one year low of $2.77 and a one year high of $15.55.

Embecta (NASDAQ:EMBC) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.15). The business had revenue of $221.80 million for the quarter, compared to the consensus estimate of $235.67 million. Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. The company’s revenue for the quarter was down 14.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.70 EPS. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. As a group, sell-side analysts expect that Embecta Corp. will post 1.62 EPS for the current fiscal year.

Embecta Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 15th. Shareholders of record on Thursday, May 28th will be given a dividend of $0.01 per share. The ex-dividend date of this dividend is Thursday, May 28th. This represents a $0.04 dividend on an annualized basis and a yield of 1.2%. Embecta’s dividend payout ratio is presently 31.58%.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.